May 25, 2026
You've done the interviews. You've checked the experience. The candidate has device sales in their background, they know the clinical environment, and they're confident in the room. Six months later, your territory is stalling, your key accounts have gone quiet, and you're back to square one.
This scenario plays out more often than most MedTech companies want to admit. And the true cost — when you add it all up — is far larger than a failed salary spend.
According to research from the Society for Human Resource Management (SHRM), the direct cost of a bad hire sits at approximately $115,000. But in MedTech sales, where clinical relationships and territory development are long-burn investments, the full picture is significantly worse. When you factor in lost deals, missed revenue targets, relationship damage, and the time spent rehiring, the total cost of a wrong sales hire can reach five to ten times that person's annual salary.
Here's where that cost actually comes from.
In MedTech, territory isn't just a geographic boundary. It's a network of relationships built over months and years with procurement teams, clinical leads, surgical nurses, and department heads. The moment a rep leaves, or worse, performs poorly and damages those relationships on the way out, that network doesn't pause. It moves to a competitor.
Rebuilding a neglected or damaged territory typically takes six to twelve months of sustained effort from a replacement hire. During that window, you're not just losing revenue — you're actively funding your competitor's growth. Every month a territory is unfilled, or filled by an underperforming rep, is a month of compounding loss.
Trust is the primary currency of MedTech sales. Surgeons, procurement managers, and clinical staff make device decisions based on confidence — in the product, yes, but also in the person representing it. A rep who overpromises, fails to follow through on clinical support, or simply doesn't show up consistently can undo years of goodwill in a matter of weeks.
Clinician relationships are not easily reset. In many cases, a bad rep doesn't just cost you the account — they hand it to a competitor who will hold it for years. That's a cost that won't appear on any P&L, but it's real, and it compounds.
MedTech onboarding is not a two-week process. Getting a rep to the point where they can credibly present your device, navigate clinical conversations, handle procurement objections, and operate independently in their territory typically takes three to six months — and that's before they're expected to be performing.
When that hire doesn't work out, every hour of product training, clinical education, shadowing, and manager time goes with them. Industry data consistently shows that companies underestimate the true cost of a failed hire by as much as three times, largely because they fail to account for the invisible cost of management time and internal disruption.
MedTech operates on procurement cycles, budget windows, and clinical trial schedules. A poorly performing rep doesn't just miss quota — they miss the window. Capital equipment decisions in hospitals often happen once a year. If your rep isn't in the room, building the case during the months before that decision lands, you don't lose the deal this quarter. You lose it for the year.
For companies in growth phases — post-funding, post-regulatory approval, or expanding into new geographies — these missed windows are particularly damaging. The commercialisation clock is ticking from the moment capital hits the balance sheet. A bad hire slows that clock at exactly the moment speed matters most.
Once you've accepted that a hire isn't working, the cost doesn't stop — it accelerates. There's the performance management process, the exit, the gap period, the re-recruitment, the second round of onboarding, and the further delay to territory performance. Industry estimates suggest that 1 in 3 sales hires fail within the first year when proper screening isn't in place. For companies that experience two or three of these cycles in a single year, the financial impact can run into the millions.
The challenge isn't that companies aren't trying to hire well. It's that MedTech sales talent is genuinely difficult to assess from the outside. Clinical credibility, consultative selling ability, relationship depth, and the specific product and therapy area knowledge required for your device are not things a CV reliably communicates. Generalist recruitment processes — built for volume, not precision — consistently miss these nuances.
The result is a hire that looks qualified, passes a standard process, and still fails in the field — because the field in MedTech demands something most hiring processes aren't designed to evaluate.
An increasing number of MedTech companies are addressing this challenge by building independent sales networks before committing to permanent headcount. Independent sales representatives — experienced, clinically credible professionals who operate on a commission basis — allow companies to establish territory coverage, test market fit, and generate commercial momentum without the fixed cost and exposure of a direct hire.
When a permanent hire is eventually made, it's informed by real market data: which territories are performing, which relationships are established, and what profile is actually succeeding in the field. The decision is de-risked because the groundwork has already been laid.
At 44 International, this is exactly the work we do. We help MedTech companies build independent sales teams that move fast, cover territory from day one, and reduce the financial risk that comes with getting commercial hiring wrong. If your company is scaling, launching into new markets, or rebuilding after a difficult hire, we'd like to talk.
© All rights reserved